Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mXELOXIRI
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
mXELOXIRI is a combination chemotherapy regimen used primarily in the treatment of advanced or metastatic colorectal cancer. The name "mXELOXIRI" stands for "modified XELOX + irinotecan," indicating it is a modified version of the XELOX (capecitabine plus oxaliplatin) regimen with the addition of irinotecan. This protocol typically includes capecitabine (an oral prodrug of 5-fluorouracil), oxaliplatin (a platinum-based chemotherapeutic), and irinotecan (a topoisomerase I inhibitor). The modification ("m") usually refers to dose adjustments or scheduling changes to improve tolerability or efficacy compared to standard regimens. These agents work synergistically by interfering with DNA synthesis and repair, leading to cancer cell death.
- Brand names
- mXELOXIRI
- Other names
- mXELOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on mXELOXIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mXELOXIRI.